Circulating neuroendocrine tumors biomarkers. Why? When? How? Suggestions for clinical practice from guidelines and consensus

Abstract

Neuroendocrine neoplasms (NETs) are rare tumors that are increasing in incidence. NETs are characterized by heterogeneous biological behaviour, clinical presentation and course. A sensitive and specific diagnostic and prognostic circulating biomarker useful for all sites, grading and staging of neuroendocrine tumors is still an unmet need. The aim of this article was to review current neuroendocrine and oncologic scientific society guidelines and position statements, and propose recommendations for the most frequent clinical practice queries on circulating neuroendocrine tumors biomarkers. The authors searched for NCCN, NANETS, ESMO, ENETS, UKINETS, AME management guidelines or position statements available from PubMed up to 7th January 2016. From these results we chose guidelines or position statements published by scientific societies or institutions in USA, Europe and Italy with recognized expertise in neuroendocrine tumor patient management. The authors present suggestions for clinical practice based on this analysis.

Keywords

Neuroendocrine tumors / neuroendocrine markers / neuroendocrine management / chromogranin A / guidelines / clinical practice

References

[1] Yao JC,Phan A,Leary C,Abdalla EK,Vauthey JN,Evans DB.One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States..J Clin Oncol26;3063-72

[2] Vinik AI,Woltering G,Warner R.Biochemical Testing for Neuroendocrine Tumors..Pancreas2009;38:876-89

[3] Vinik AI.New and emerging syndromes due to neuroendocrine tumors..Endocrinol Metab Clin North Am2011;40:19-63

[4] Metz DC,Strosberg J,Howden CW,Yao JC.A rationale for multidisciplinary care in treating neuroendocrine tumours..Curr Opin Endocrinol Diabetes Obes2012;19:306-13

[5] Grimaldi F,Attanasio R,Papini E,Baldelli R,Bianchetti S,Caputo M,Cremonini N,Davı MV,Faggiano A,Versari A,Rindi G.Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms..J Endocrinol Invest2014;37:875-909 PMCID:PMC4159596

[6] Vinik AI.Clinical presentation and diagnosis of neuroendocrine tumors..Hematol Oncol Clin N Am2016;30:21-48

[7] Modlin IM,Bornschein J.Evolution of the Diffuse Neuroendocrine System - Clear Cells and Cloudy Origins..Neuroendocrinology2006;84:69-82

[8] Oberg K.Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours..Endocr Relat Cancer2011;18 Suppl 1:S17-25

[9] Kanakis G.Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs)..Best Pract Res Clin Gastroenterol2012;26:791-802

[10] Bosman FT.World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Digestive System..Lyon: IARC Press2010;

[11] Kloppel G,Perren A,McNicol AM,Scarpa A,Wiedenmann B,Rindi G,and all other Mallorca Consensus Conference participants..ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Towards a Standardized Approach to the Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors and Their Prognostic Stratification..Neuroendocrinology2009;90:162-6

[12] Oberg K,De Herder W,Klimstra D,Metz DC,Kwekkeboom D,Meyer T,Washington K,Liu E.Consensus on biomarkers for neuroendocrine tumour disease..Lancet Oncol2015;16:435-46

[13] Lawrence B,Kidd M,Svejda B.The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors..Endocrinol Metab Clin North Am2011;40:111-34

[14] Modlin IM,Moss SF,Tsolakis AV.Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease..Ann Surg Oncol2010;17:2427-43

[15] Giusti M,Augeri C,Minuto F.Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man..Eur J Endocrinol2004;150:299-303

[16] Yang X,Li Z,Yang T,Liu L.Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis..PLoS One2015;10:e0124884

[17] Zatelli MC,Leon A,Gion M,De Braud F,Dogliotti L.Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study..Endocr Relat Cancer2007;14:473-82

[18] Bajetta E,Martinetti A,Procopio G,Zilembo N,Seregni E.Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors..Cancer1999;86:858-65

[19] Janson ET,Stridsberg M,Theodorsson E,Oberg K.Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center..Ann Oncol1997;8:685-90

[20] Sherman SK,O'Dorisio MS,Howe JR.Pancreastatin predicts survival in neuroendocrine tumors..Ann Surg Oncol2014;21:2971-80 PMCID:PMC4125469

[21] Frank R.Clinical biomarkers in drug discovery and development..Nat Rev Drug Discov2003;2:566-80

[22] Jensen RT,Brandi ML,Kaltsas G,Scoazec JY,Sauvanet A,Barcelona Consensus,Barcelona Consensus Conference participants..ENETS Consensus Guidelines for the Management of Patient with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes..Neuroendocrinology2012;95:98-119

[23] Cryer PE,Grossman AB,Montori VM,Service FJ.Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline..J Clin Endocrinol Metab2009;94:709-28

[24] Kon T,Suzuki R,Ebina Y.VIP and calcitonin-producing pancreatic neuroendocrine tumor with watery diarrhea: clinicopathological features and the effect of somatostatin analogue..JOP2012;13:226-30

[25] Falconi M,Kaltsas G,Capdevila J,Kos-Kudla B,Rindi G,Reed N,Jensen RT.Consensus Guidelines Update for the Management of Functional p-NETs (F-p-NETs) and Non-Functional p-NETs (NF-p-NETs)..Neuroendocrinology2016;103:153-71

[26] Boscaro M.Approach to the Patient with Possible Cushing's Syndrome..J Clin Endocrinol Metab2009;94:3121-31

[27] Grohé C Berardi R.Hyponatraemia-SIADH in lung cancer diagnostic and treatment algorithms..Crit Rev Oncol Hematol2015;96:1-8

[28] Barakat MT,Bloom SR.Neuroendocrine tumours..Endocr Relat Cancer2004;11:1-18

[29] Kunz PL,Anthony LB,Brendtro K,Chen H,Kim MK,Kulke MH,Metz DC,Sippel RS,Yao JC.Consensus guidelines for the management and treatment of neuroendocrine tumors..Pancreas2013;42:557-77 PMCID:PMC4304762

[30] Jilesen AP,van Gulik TM,Nieveen van Dijkum EJ.Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors--diagnostic accuracy: NF-pNET and low tumor burden..Dig Surg2014;31:407-14

[31] O'Toole D,Gross D,Barkmanova J,Pape UF,all other Mallorca Consensus Conference participants..ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers..Neuroendocrinology2009;90:194-202

[32] Kulke MH,Benson AB3rd,Berlin JD,Emerson L,Fanta P,Goldner WS,Heslin MJ,Kunz PL,Lieu C,Munene G,Saltz L,Strosberg JR,Wolfgang C,Burns J,National comprehensive cancer network..Neuroendocrine tumors, version 1.2015..J Natl Compr Canc Netw2015;13:78-108

[33] Ramage JK,Ardill J,Breen DJ,Corrie P,Davies AH,Meyer T,Poston G,Rockall A,Thakker RV,Valle J,Grossman AB.Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)..Gut2012;61:6-32 PMCID:PMC3280861

[34] Yao JC,Phan AT,Hoosen S.Peter J, Cherfi A, Öberg KE. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus..J Clin Endocrinol Metab2011;96:3741-9

[35] van Adrichem RC,Vandamme T,Feelders RA.Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors..Ann Oncol2015;27:746-7

[36] Kulke MH,Tepper JE,Jaffe D,Ellis LM,Bergsland EK,Van Cutsem E,Oberg K,Posner MC.Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting..J Clin Oncol2011;29:934-43 PMCID:PMC3068065

[37] Vinik AI,Warner RP,O'Dorisio TM,Coppola D.NANETS Consensus Guidelines for the diagnosis of neuroendocrine tumor..Pancreas2010;39:713-34

[38] Phan AT,Choi J,Hassan MM,Krenning EP,Woltering EA.NANETS Consensus Guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus)..Pancreas2010;39:784-98

[39] Boudreaux JP,Hassan MM,Jensen RT,Nutting CDO,Caplin ME.The NANETS Consensus Guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum..Pancreas2010;39:753-66

[40] Kulke MH,Bushnell DL,Goldsmith SJ,Marx SJ,Pommier RF,Jensen RT.NANETS Treatment Guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas..Pancreas2010;39:735-52 PMCID:PMC3100728

[41] Öberg K,Kwekkeboom D.Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up..Annals Oncol2012;23:124-30

[42] Öberg K,Ferolla P.Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up..Ann Oncol2012;23:120-3

[43] Caplin ME,Ferolla P,Garcia-Yuste M,Oberg K,Perren A,Travis WD.Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids..Ann Oncol2015;26:1604-20

[44] Niederle B,Costa F,Kelestimur F,Öberg K,Perren A,O'Connor J,Krenning E,Kianmanesh R.ENETS Consensus Guidelines Update for Neuroendocrine Neoplasm of the Jejunum and Ileum..Neuroendocrinology2016;103:125-38

[45] Frilling A,Kidd M,Breitenstein S,Kwekkeboom D,Klersy C,Davidson B,Caplin M,Schilsky R.Recommendations for management of patients with neuroendocrine liver metastases..Lancet Oncol2014;15:8-21

[46] Berna MJ,Serrano J,Jensen RT.Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature..Medicine (Baltimore)2006;85:295-330

[47] Massironi S,Sciola V,Ciafardini C,Rossi RE.Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors..Am J Gastroenterol2010;105:2072-8

[48] Massironi S,Casazza G,Ciafardini C,Peracchi M.Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution..Neuroendocrinology2014;100:240-9

[49] Rossi RE,Meyer T,Watkins J,Caplin ME.Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours..Ann Transl Med2015;3:118

[50] Jensen EH,McLoughlin JM,Alvarado MD,Malafa M.Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors..Ann Surg Oncol2007;14:780-5

[51] Kwekkeboom DJ,Bakker WH,de Herder WW,van Eijck CH,Kam BL.Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors..J Clin Oncol2005;23:2754-62

[52] Olausson M,Herlenius G,Nilsson O,Wängberg B.Orthotopic liver or multivisceraltransplantation as treatment of metastatic neuroendocrine tumors..Liver Transpl2007;13:327-33

[53] Modlin IM,Alaimo D,Teixiera N,Kidd M.A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection..Endocr Relat Cancer2014;21:615-28

[54] Modlin IM,Bodei L,Kidd M.A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors..Endocr Connect2014;3:215-23

[55] Khan MS,Tsigani T,Hartley JA,Meyer T.Circulating tumor cells as prognostic markers in neuroendocrine tumors..J Clin Oncol2013;31:365-72

[56] Khan MS,Tsigani T,Goldstein R,Caplin ME.Early changes in circulating tumor cells are associated with response and survival following treatment of metastatic neuroendocrine neoplasms..Clin Cancer Res2016;22:79-85

[57] Modlin IM,Chung DC,Snyderwine E.Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors..J Natl Cancer Inst2008;100:1282-9 PMCID:PMC2538549